Research programme: peptides - Enteris BioPharma/KeyBioScience
Latest Information Update: 04 Oct 2013
At a glance
- Originator Enteris BioPharma; KeyBioScience
- Class Peptides
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Obesity; Type 2 diabetes mellitus
Most Recent Events
- 30 Sep 2013 Early research in Obesity in USA (PO)
- 30 Sep 2013 Early research in Type-2 diabetes mellitus in USA (PO)